Introduction
Though a few investigations have failed to show any connexion between analgesic intake and renal disease (Lawson, 1973; Waters et al., 1973) most nephrologists accept analgesic nephropathy as an established entity (Abel, 1971; Burry, 1971; Clarkson and Lawrence, 1971; Gault et al., 1971; Murray et al., 1971; Kingsley et al., 1972; Linton, 1972; Wilson, 1972; CoveSmith and Knapp, 1973) . In contrast to this near unanimity on the nature of the disease is a continuing dispute about its cause. After Spiihler and Zollinger's (1953) description phenacetin emerged as the one common ingredient in the varied mixtures of analgesic, sedative, opiate, and stimulant drugs incriminated. Most workers regarded it as the major or only cause of the disease (see Lawson and Maclean, 1966; Shelley, 1967, for review) . The epidemiological evidence has continued to impress some authors, who have retained the name "phenacetin" in their descriptions of the disease or recommended restrictions on the sale of the drug (Bell et al., 1969; Bengsston, 1969; Raaflaub and Dubach, 1969, 1972; Koutsaimanis and de Wardener, 1970; de Wardener and Koutsaimanis, 1971; Dubach, 1971; Sanerkin, 1971) .
Phenacetin is not an indispensible drug; its withdrawal from one British hospital caused no regrets (Hart et al., 1970) . In Sweden sales of phenacetin over the counter were banned in 1961 while aspirin and phenazone remained on free sale; the incidence of the disease fell (Bengsston, 1969; Nordenfelt, 1972) . A similar decline in the incidence of analgesic nephropathy resulted from the replacement of phenacetin by other analgesics in proprietary mixtures popular in South West Scotland . Several other countries have restricted or discouraged the sale of phenacetin (Bishop et al., 1972) .
On the other hand there is a strong body of opinion that phenacetin has been singled out prematurely (Gilman, 1964; Shelley, 1967; Gault et al., 1968; Prescott, 1969 Prescott, , 1970 Prescott, , 1971 Kincaid-Smith, 1970 a, b; Abel, 1971; Gault, 1972) . It is rarely taken alone and many of the drugs with which it is commonly combined, or their metabolites, are nephrotoxic to some animals under some circumstances (Saker and Kincaid-Smith, 1969; Nanra and Kincaid-Smith, 1970; Calder et al., 1971 Calder et al., , 1972 Nanra et al., 1971) . Consequently "analgesic nephropathy" has replaced "phenacetin kidney" as the common title for the disease (British MedicalJournal, 1965 and some workers regard other analgesics, particularly aspirin, with such grave suspicion that they call for restrictions on the sale of all common analgesics . This would be a much greater curtailment of personal convenience than merely the withdrawal of a single drug, however, and rigid restrictions on the sale of aspirin would be particularly troublesome to rheumatologists (Scott, 1966) , who often prescribe aspirin alone in total doses of many kilograms for the treatment of rheumatoid arthritis.
We therefore looked for evidence of chronic renal disease in patients attending a rheumatology clinic who had taken large quantities of aspirin without also taking appreciable quantities of any other drugs suspected of causing renal damage. We defined "heavy aspirin consumption" as a total intake of 5 kg or more since the patients in three reported series who developed analgesic nephropathy from aspirin-phenacetin mixtures had typically consumed at least this amount of aspirin (Gault et al., 1968; range Male patients.
..l and age, were not unexpected. Burry (1970) found a creatinine clearance below 80 ml/min in 49 out of 97 unselected patients with rheumatoid arthritis and he showed a correlation between reduction in glomerular filtration rate and severity of articular erosions on radiographs. All our patients had radiological evidence of severe rheumatoid arthritis. There is no accepted renal lesion of rheumatoid arthritis, however, so these observed depressions of filtration rate may reflect early involvement of the kidneys by amyloidosis, glomerulonephritis, or analgesic nephropathy. None of our patients had features of amyloidosis or glomerulonephritis but these cannot be totally excluded without renal biopsy, which in our cases was not justified. The obvious conclusion from our study and that of Bulger et al. (1968) is that aspirin given alone in the doses commonly prescribed for rheumatoid arthritis rarely if ever causes serious renal disease. There is, however, an objection to such point-intime studies. Possibly analgesic nephropathy affects only a small minority of the population who are unduly sensitive because of slow hepatic inactivation of the causative drug or some other factor. Such patients would be eliminated from the rheumatology clinic by early death from analgesic nephropathy and would be under-represented in a cross sectional study. As a partial check on the possibility that Newcastle patients are dying early from aspirin nephropathy we examined the case notes of all patients who had died in the Royal Victoria Infirmary in the last five years with a clinical or pathological diagnosis of both rheumatoid arthritis and renal failure. There is a high probability that any patient attending our rheumatology clinic who had died in hospital would have done so in the Royal Victoria Infirmary. Of the six patients who met these criteria only one had analgesic nephropathy; he had consumed between 3 and 6 kg of phenacetin as Sonalgin. One patient had died in uraemia without a primary diagnosis. There was no necropsy, but there was no history of heavy analgesic intake. The four other patients had firm pathological evidence of unrelated renal disease. Ideally this evidence for the lack of aspirin nephrotoxicity should be tested by a prospective trial of aspirin takers as planned in New Zealand (Wigley, 1971) . Decades of observation will probably be needed, however, to provide a firm answer in a population of 3 million.
It would be unsafe to extrapolate our results to patients taking aspirin in drug mixtures, in climates hotter than those of England or the State of Washington (Bulger et al., 1968) , or in the very high dosage (up to 30 g/day) sometimes adopted by drug habitues . So far as they go, however, our results contradict the growing belief that aspirin is the most nephrotoxic of the common analgesics. The following evidence has been given for this belief.
Firstly, animal studies, reviewed by Nanra et al. (1971) , which suggested that aspirin, alone or in combination with phenacetin, is more nephrotoxic than phenacetin alone. Though important these studies can be applied to man only with great reserve.
Secondly, the occurrence of analgesic nephropathy in seven patients who gave no history of taking phenacetin and whose major drug consumption was of aspirin (Harvald, 1963; Lawson and MacLean, 1966; Olaffson et al., 1966; Prescott, 1969; Murray et al., 1971 ). An eighth case was withdrawn after the discovery of methaemoglobinaemia (A. A. H. Lawson, personal communication to J. T. Scott). These cases have to be set against the massive international consumption of aspirin, which, unlike phenacetin, is often prescribed alone; against the far more numerous cases associated with phenacetin; and against the formidable difficulty of excluding forgotten drug consumption. It must be admitted, however, that drug abusers usually choose drug mixtures (Murray, 1972 b) .
Thirdly, the high incidence of papillary necrosis at necropsy in rheumatoid patients at certain centres. Papillary necrosis was found in 17 consecutive necropsies by Nanra and colleagues (1970, 1971 ) and aspirin was blamed by implication. The drug histories of these 17 patients have never been published, however, and the high incidence of papillary necrosis has been reported only from centres where aspirin-phenacetin mixtures have been popular (Clausen and Pedersen, 1961; Lawson and MacLean, 1966; Nanra et al., 1971) . The disease is relatively rare in Newcastle and the State of Washington (Bulger et al., 1968) where rheumatologists have never been in the habit of prescribing such mixtures. The differences may have other explanations but climate is unlikely to enter into a contrast between Edinburgh and Newcastle.
Lastly, relapses in patients with analgesic nephropathy when they consumed aspirin-containing mixtures without phenacetin Murray et al., 1971) . Such reports are not easy to evaluate. In all the six cases reported in detail by Kincaid-Smith et al. (1971) the deterioration in renal function was associated with urinary obstruction by sloughed papillae; this might have been a sign of renewed activity of the disease but it is also an accident that could have occurred in the absence of analgesic intake.
We conclude that the case against aspirin is very weak and that there is no need to restrict its sale on the basis of nephrotoxicity. Is there indeed any need to restrict the sale of any analgesic? The studies of Sorensen (1966) , Lawson (1973) , and Waters et al. (1973) which showed a low prevalence of renal disease in subjects who had consumed several kilograms of analgesic mixtures-usually containing both aspirin and phenacetin-suggest that there is not. These mixtures, however, do play a key role in analgesic abuse (Murray and Smith, 1972) , possibly because of the uplift provided by other ingredients such as caffeine. It would seem reasonable to provide at least a "Government health warning" on each packet (Bishop et al., 1972) .
We still feel that the most likely culprit in analgesic nephropathy is phenacetin. Since it is so rarely consumed alone direct prospective studies of its role are impracticable and it must be judged on indirect evidence. In view of the encouraging results from Scandinavia (Nordenfelt, 1972) and South-west Scotland a) a national experiment on a larger scale on its restriction seems to us justifiable and we would welcome moves to limit its sale to "prescription only" in Britain, provided we can first arrange adequate data collection to ensure that the experiment really gives an answer.
Lung perfusion scanning is of value in the diagnosis of pulmonary embolism and is a simple and safe screening proced- ure. Interpreta-tion of lung scans, however, creates a problem in some patients because abnormal perfusion is not peculiar -to pulmonary embolism but can appear in a variety of lung diseases, including bronchitis and asthma (Lopez-Majano et al., 1966; Mishkin and Wagner, 1968) . There is a need for a reliable method of diagnosing emboli in patienrts with asthma, bronchitis, and other conditions with impaired pulmonary perfusion.
Animal studies show itha-t a reduction in lung ventilation such as occurs in man with chronic obstructive airways diseases leads rapidly to a corresponding reduction in lung perfusion. On the other hand, reduction in lung perfusion, as in pulmonary embolism, does not lead to a correspondingly marked and sustained reduction in ventilation. With this in mind several workers have suggested that combined ventilation-perfusion lung scans might aid more specific diagnosis of pulmonary embolism (De Nardo et al., 1970; Farmelan(t and Trainor, 1971) . Their studies were made on a total of 57 pa-tients and the results justified a clinical trial with a larger series. We have therefore performed 100 combined ventilation-perfusion lung scans on patients with pulmonary problems and have assessed the results in relation to the final diagnosis.
Patients and Methods
The patients had been routinely referred by clinicians in the hospital. Both scans were performed at the same session, vetila-tion scanning always preceding perfusion scanning. The combined scans took 20 minutes. Perfusion images were obtained by using macroaggregated albumin (MAA) labelled with 99mTc. Gaseous l13Xe was used for ventilation imagig. All the images were recorded on Polaroid film by means of a Nuclear Enterprises mark III ganmm camera with a diverg-
